OBJECTIVE: ¹⁸F-fluorodeoxyglucose positron emission tomography (FDG PET) has been shown to improve the accuracy of staging in oesophageal cancer. We assessed the benefit of PET/CT over conventional staging and determined if tumour histology had any significant impact on PET/CT findings. METHODS: A retrospective cohort study, reviewing the results from 200 consecutive patients considered suitable for radical treatment, undergoing routine PET/CT staging comparing the results from CT and endoscopic ultrasound, as well as multi-disciplinary team records. Adenocarcinoma and squamous cell carcinoma were compared for maximum Standardised Uptake Value (SUV(max)), involvement of local lymph nodes and distant metastases. RESULTS: PET/CT provided additional information in 37 patients (18.5%) and directly altered management in 34 (17%): 22 (11%) were upstaged; 15 (7.5%) were downstaged, 12 of whom (6%) received radical treatment. There were 11 false negatives (5.5%) and 1 false positive (0.5%). SUV(max) was significantly lower for adenocarcinoma than squamous cell carcinoma (median 9.1 versus 13.5, p = 0.003). CONCLUSIONS: Staging with PET/CT offers additional benefit over conventional imaging and should form part of routine staging for oesophageal cancer. Adenocarcinoma and squamous cell carcinoma display significantly different FDG-avidity.
OBJECTIVE: ¹⁸F-fluorodeoxyglucose positron emission tomography (FDG PET) has been shown to improve the accuracy of staging in oesophageal cancer. We assessed the benefit of PET/CT over conventional staging and determined if tumour histology had any significant impact on PET/CT findings. METHODS: A retrospective cohort study, reviewing the results from 200 consecutive patients considered suitable for radical treatment, undergoing routine PET/CT staging comparing the results from CT and endoscopic ultrasound, as well as multi-disciplinary team records. Adenocarcinoma and squamous cell carcinoma were compared for maximum Standardised Uptake Value (SUV(max)), involvement of local lymph nodes and distant metastases. RESULTS: PET/CT provided additional information in 37 patients (18.5%) and directly altered management in 34 (17%): 22 (11%) were upstaged; 15 (7.5%) were downstaged, 12 of whom (6%) received radical treatment. There were 11 false negatives (5.5%) and 1 false positive (0.5%). SUV(max) was significantly lower for adenocarcinoma than squamous cell carcinoma (median 9.1 versus 13.5, p = 0.003). CONCLUSIONS: Staging with PET/CT offers additional benefit over conventional imaging and should form part of routine staging for oesophageal cancer. Adenocarcinoma and squamous cell carcinoma display significantly different FDG-avidity.
Authors: Henderik L van Westreenen; John T M Plukker; David C P Cobben; Carolien J M Verhoogt; Henk Groen; Pieter L Jager Journal: AJR Am J Roentgenol Date: 2005-08 Impact factor: 3.959
Authors: Bryan F Meyers; Robert J Downey; Paul A Decker; Robert J Keenan; Barry A Siegel; Robert J Cerfolio; Rodney J Landreneau; Carolyn E Reed; Dennis M Balfe; Farrokh Dehdashti; Karla V Ballman; Valerie W Rusch; Joe B Putnam Journal: J Thorac Cardiovasc Surg Date: 2007-03 Impact factor: 5.209
Authors: Johannes B Roedl; Dushyant V Sahani; Rivka R Colen; Alan J Fischman; Peter R Mueller; Michael A Blake Journal: Eur Radiol Date: 2008-07-24 Impact factor: 5.315
Authors: Richard G Berrisford; Wei-Lup Wong; David Day; Elizabeth Toy; Mark Napier; Keith Mitchell; Saj Wajed Journal: Eur J Cardiothorac Surg Date: 2008-03-06 Impact factor: 4.191
Authors: Vlad V Simianu; Thomas K Varghese; Meghan R Flanagan; David R Flum; Veena Shankaran; Brant K Oelschlager; Michael S Mulligan; Douglas E Wood; Carlos A Pellegrini; Farhood Farjah Journal: J Gastrointest Oncol Date: 2016-06
Authors: John M Findlay; Richard S Gillies; James M Franklin; Eugene J Teoh; Greg E Jones; Sara di Carlo; Fergus V Gleeson; Nicholas D Maynard; Kevin M Bradley; Mark R Middleton Journal: Eur Radiol Date: 2016-02-16 Impact factor: 5.315
Authors: R S Gillies; M R Middleton; C Blesing; K Patel; N Warner; R E K Marshall; N D Maynard; K M Bradley; F V Gleeson Journal: Eur Radiol Date: 2012-05-05 Impact factor: 5.315